Patents Assigned to ILAB
  • Patent number: 11850230
    Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: December 26, 2023
    Assignee: ILAb
    Inventors: Tae-Hwe Heo, Kye Jung Shin
  • Publication number: 20230271925
    Abstract: The present invention relates to a novel TNF activity inhibitor compound and a pharmaceutically acceptable salt thereof, a method for prevention, alleviation or treatment comprising administering the compound of the present invention, a method for preparing the compound of the present invention, and a pharmaceutical composition comprising the compound.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 31, 2023
    Applicant: ILAb Co., Ltd.
    Inventor: Kyung Yeon Park
  • Patent number: 11689540
    Abstract: A device for a secure data connection of at least one manufacturing machine (104) has an information-processing system (114), which is subdivided into individual zones (108, 110, 112) interconnected by data diodes (120) such that data originating from the machine control (118) of the manufacturing machine (104) in a data flow can be transferred to other zones (108, 110, 112) without the possibility of a data return flow. The individual zones (110, 112) are ordered hierarchically. Each individual zone has a lower level of data security than the upstream individual zone (108, 110) in relation to the data flow. Every individual zone (108, 110, 112) is formed as an independent computer in the manner of an isolated application. In addition, a manufacturing machine and a production plant includes the device for secure data connection.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: June 27, 2023
    Assignee: ROMMELAG ILABS GMBH
    Inventors: Gert Hansen, Helmut Jacob
  • Publication number: 20230150928
    Abstract: The present invention relates to a method for preparing 2-(2,5-difluorophenyl)-3-carboxy-7-chloro-(4H)-4-benzopyranone represented by formula 1 below, a novel intermediate used therein, and a method for preparing the same. Specifically, an object of the present invention is to provide a novel preparation method, in which the compound of formula 1 below can be efficiently and economically synthesized and can be mass-produced in a high yield.
    Type: Application
    Filed: March 17, 2021
    Publication date: May 18, 2023
    Applicant: ILAb
    Inventor: Suk Ho LEE
  • Publication number: 20230099574
    Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
    Type: Application
    Filed: October 6, 2022
    Publication date: March 30, 2023
    Applicant: ILAb
    Inventors: Tae-Hwe HEO, Kye Jung Shin
  • Patent number: 11504349
    Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 22, 2022
    Assignee: ILAB
    Inventors: Tae-Hwe Heo, Kye Jung Shin
  • Publication number: 20200246304
    Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
    Type: Application
    Filed: July 12, 2018
    Publication date: August 6, 2020
    Applicant: ILAB
    Inventors: Tae-Hwe Heo, Kye Jung Shin